January 3, 2024 7:38am

 

The Nasdaq registered its worst session since October while the cell and gene therapy sector popped - yesterday

Pre-open Indications: 1 Positive and 1 Negative Indications

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

 

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

The pre-open Dow futures are DOWN -0.27% or (-103 points), the S&P is DOWN -0.36% or (-17 points) as the Nasdaq is DOWN -0.55% (-92 points)

Stock futures fell Wednesday,

Europe markets open mixed,

Asia-Pacific markets fell

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed Tuesday with the Dow closing UP +25.50 points or +0.07%, the S&P closed DOWN -27 points or -0.57% while the Nasdaq closed DOWN -245.41 points or -1.63%

Economic Data Docket: JOLTS Job Openings, November (8.85 million expected, 8.73 million previously); ISM Manufacturing, December, (47.2 expected, 46.7 previously); ISM prices paid, December (49.9 previously); FOMC meeting minutes

 

Tuesday, RegMed Investors (RMi) Closing Bell: “market trips, licensing news juices the cell and gene therapy sector for a while in session” … https://www.regmedinvestors.com/articles/13267

 

Q1/24: 1 holiday and 1 positive close

Q4:

  • December – 1 holiday, 10 positive and 10 negative closes
  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Potential …

Positive Indications:

Tuesday’s closing price, Monday was holiday, some Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed down -$1.17 after Monday’s holiday and Friday’s +$0.89. Thursday’s -$1.49 and last Wednesday’s +$2.03 with a positive +$1.82 or +2% pre-open indication.

 

Negative Indications:

Tuesday’s closing price, Monday was holiday, some Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed up +$3.46 after Monday’s holiday and Friday’s -$1.70, Thursday’s -$0.66, Wednesday’s -$0.37 with a negative -$0.26 or -0.39% pre-open indication.

 

The BOTTOM LINE: Yesterday’s gold could be today’s tin!

  • U.S. stock index futures slipped on Wednesday, pointing to fresh losses on the 2nd trading day of 2024, as Treasury yields extended gains ahead of data that could … offer insight into the Fed's monetary policy.
  • The stock market rally started 2024 with a mixed-to-weak performance Tuesday, with tech growth leaders near highs leading the retreat <IBD> … while the cell and gene therapy beat some expectation! <me>
  • I have many a concern of sentiment and conviction in the cell and gene therapy sector.
  • I STILL believe the sector is headed into “correction” which means that investors should remain cautious as “our” universe skips into Q4 and 2023’s end earnings’ LPS (loss-per-share) reporting.

12/29/23 ended with my message of: “Looking toward 2024 with one word – recalibration i.e., a change in the way you do or think about something – markets and the cell and gene therapy sector.”

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • The first week of trading in 2024 will instantly put the rally to the test with a crucial December jobs report slated for release on Friday morning.
  • The economic calendar will also feature meeting notes from the Fed, the latest update on job openings and fresh data on activity in the manufacturing and services sectors.

News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's a good time to wait and see which stocks stand out after early-January shakeouts.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.